Related references
Note: Only part of the references are listed.PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future
Ricky Chen et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
The challenges associated with molecular targeted therapies for glioblastoma
Toni Rose Jue et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas
Panagiotis Korfiatis et al.
MEDICAL PHYSICS (2016)
Isocitrate Dehydrogenase (IDH) 1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
Jun-Rui Chen et al.
MEDICINE (2016)
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Xiaoman Li et al.
ONCOTARGET (2016)
Glioma Stem Cells: Signaling, Microenvironment, and Therapy
Brandon D. Liebelt et al.
STEM CELLS INTERNATIONAL (2016)
Glioblastoma: pathology, molecular mechanisms and markers
Kenneth Aldape et al.
ACTA NEUROPATHOLOGICA (2015)
Molecular Pathways in Gliomagenesis and Their Relevance to Neuropathologic Diagnosis
Christina L. Appin et al.
ADVANCES IN ANATOMIC PATHOLOGY (2015)
Progress in the application of molecular biomarkers in gliomas
Jing Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Isocitrate dehydrogenase mutations: new opportunities for translational research
Young-Sam Keum et al.
BMB REPORTS (2015)
Advances in the treatment of newly diagnosed glioblastoma
Brett J. Theeler et al.
BMC MEDICINE (2015)
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Michael Weller et al.
CLINICAL CANCER RESEARCH (2015)
A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: Analysis of 14,678 patients using systematic review and meta-analytical tools
Matthew N. T. Thuy et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
Clinical impact of molecular biomarkers in gliomas
Tali Siegal
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
Stem cell signature in glioblastoma: therapeutic development for a moving target
Ichiro Nakano
JOURNAL OF NEUROSURGERY (2015)
EGFR Amplified and Overexpressing Glioblastomas and Association With Better Response to Adjuvant Metronomic Temozolomide
Manuela Cominelli et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Glioblastoma multiforme: Pathogenesis and treatment
Constantinos Alifieris et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Peritumoral edema on magnetic resonance imaging predicts a poor clinical outcome in malignant glioma
Chen-Xing Wu et al.
ONCOLOGY LETTERS (2015)
EGFR Amplified and Overexpressing Glioblastomas and Association With Better Response to Adjuvant Metronomic Temozolomide
Manuela Cominelli et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma
Emily Padfield et al.
FRONTIERS IN ONCOLOGY (2015)
EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers
Claire Faulkner et al.
BRITISH JOURNAL OF NEUROSURGERY (2015)
Ipilimumab and whole brain radiation therapy for melanoma brain metastases
Naamit K. Gerber et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2015)
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Anna Sophie Berghoff et al.
NEURO-ONCOLOGY (2015)
Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification
A. Gupta et al.
CLINICAL NEURORADIOLOGY (2015)
OPINION Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma
Frank B. Furnari et al.
NATURE REVIEWS CANCER (2015)
The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse Glioma
Jason T. Huse et al.
CLINICAL CANCER RESEARCH (2014)
Emerging treatment strategies for glioblastoma multiforme
Steven K. Carlsson et al.
EMBO MOLECULAR MEDICINE (2014)
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy
Michael Weller et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection
Jason Beiko et al.
NEURO-ONCOLOGY (2014)
Molecular and cellular heterogeneity: the hallmark of glioblastoma
Diane J. Aum et al.
NEUROSURGICAL FOCUS (2014)
AKT Pathway Genes Define 5 Prognostic Subgroups in Glioblastoma
Anna Joy et al.
PLOS ONE (2014)
Current Vaccine Trials in Glioblastoma: A Review
LindaW. Xu et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Potential Role of Preoperative Conventional MRI Including Diffusion Measurements in Assessing Epidermal Growth Factor Receptor Gene Amplification Status in Patients with Glioblastoma
R. J. Young et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2013)
MGMT Promoter Methylation and Glioblastoma Prognosis: A Systematic Review and Meta-analysis
Yang Chen et al.
ARCHIVES OF MEDICAL RESEARCH (2013)
Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma
Krishna P. L. Bhat et al.
CANCER CELL (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
The Definition of Primary and Secondary Glioblastoma
Hiroko Ohgaki et al.
CLINICAL CANCER RESEARCH (2013)
Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages
Orin Bloch et al.
CLINICAL CANCER RESEARCH (2013)
Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
Terri S. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients
Yawei Liu et al.
JOURNAL OF NEUROSCIENCE (2013)
Molecular neuro-oncology in clinical practice: a new horizon
Michael Weller et al.
LANCET ONCOLOGY (2013)
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Shota Tanaka et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective
Benedikt Wiestler et al.
NEURO-ONCOLOGY (2013)
Reoperations of patients with low-grade gliomas in eloquent or near eloquent brain areas
Wojciech Kaspera et al.
NEUROLOGIA I NEUROCHIRURGIA POLSKA (2013)
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Wolfgang Wick et al.
NEUROLOGY (2013)
Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis
Vibeke A. Larsen et al.
NEURORADIOLOGY (2013)
EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms
C. A. Del Vecchio et al.
ONCOGENE (2013)
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Andrea Sottoriva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3
Ping Mao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle et al.
SCIENCE (2013)
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang et al.
SCIENCE (2013)
Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding
Arshawn Sami et al.
TUMOR BIOLOGY (2013)
Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas
Tiffany Doucette et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Paradoxical Relationship Between the Degree of EGFR Amplification and Outcome in Glioblastomas
Jonathan Hobbs et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Glioblastoma biomarkers from bench to bedside: advances and challenges
Gina Farias-Eisner et al.
BRITISH JOURNAL OF NEUROSURGERY (2012)
The assessment of prognostic factors in surgical treatment of low-grade gliomas: A prospective study
Krzysztof Majchrzak et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2012)
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation
Christopher G. Duncan et al.
GENOME RESEARCH (2012)
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
Guido Reifenberger et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study
Whitney B. Pope et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
11C-Methionine PET for Grading and Prognostication in Gliomas: A Comparison Study with 18F-FDG PET and Contrast Enhancement on MRI
Tarun Singhal et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2
Rumela Chakrabarti et al.
NATURE CELL BIOLOGY (2012)
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy
Huilin Shao et al.
NATURE MEDICINE (2012)
2-hydroxyglutarate detection by magnetic resonance spectroscopy in subjects with IDH-mutated gliomas
Changho Choi et al.
NATURE MEDICINE (2012)
Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2012)
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice
Michael Weller et al.
NEURO-ONCOLOGY (2012)
Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas
Benjamin M. Ellingson et al.
NEUROIMAGE (2012)
Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients
Brendan Fong et al.
PLOS ONE (2012)
Percent Change of Perfusion Skewness and Kurtosis: A Potential Imaging Biomarker for Early Treatment Response in Patients with Newly Diagnosed Glioblastomas
Hye Jin Baek et al.
RADIOLOGY (2012)
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Devendra Singh et al.
SCIENCE (2012)
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
Cytotoxic T-Lymphocyte-Associated Antigen-4
April K. S. Salama et al.
CLINICAL CANCER RESEARCH (2011)
Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
Nanne K. Kloosterhof et al.
LANCET ONCOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited
Nicola Montano et al.
NEOPLASIA (2011)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Correlation of 6-18F-Fluoro-L-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas
Barbara J. Fueger et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism
Zachary J. Reitman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
Andreana L. Rivera et al.
NEURO-ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
Jason T. Huse et al.
NATURE REVIEWS CANCER (2010)
Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements
L. S. Hu et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2009)
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2009)
Overall Survival of Newly Diagnosed Glioblastoma Patients Receiving Carmustine Wafers Followed by Radiation and Concurrent Temozolomide Plus Rotational Multiagent Chemotherapy
Mary Lou Affronti et al.
CANCER (2009)
Genetic alterations and signaling pathways in the evolution of gliomas
Hiroko Ohgaki et al.
CANCER SCIENCE (2009)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Sumihito Nobusawa et al.
CLINICAL CANCER RESEARCH (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Koichi Ichimura et al.
NEURO-ONCOLOGY (2009)
Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study
Izabela Zawlik et al.
NEUROEPIDEMIOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging
Ramon F. Barajas et al.
RADIOLOGY (2009)
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Shimin Zhao et al.
SCIENCE (2009)
Regional hypoxia in glioblastoma multiforme quantified with [18F] fluoromisonidazole positron emission tomography before radiotherapy:: Correlation with time to progression and survival
Alexander M. Spence et al.
CLINICAL CANCER RESEARCH (2008)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers
Johan Skog et al.
NATURE CELL BIOLOGY (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules
Maximilian Diehn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
FET PET for the evaluation of untreated gliomas:: correlation of FET uptake and uptake kinetics with tumour grading
Gabriele Poepperl et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Frank B. Furnari et al.
GENES & DEVELOPMENT (2007)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Molecularly targeted therapy for malignant glioma
Sith Sathornsumetee et al.
CANCER (2007)
Lessons learned in the development of targeted therapy for malignant gliomas
Antonio M. P. Omuro et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
Christopher E. Pelloski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Genetic pathways to primary and secondary glioblastoma
Hiroko Ohgaki et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Gefitinib in patients with progressive high-grade gliomas:: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
E. Franceschi et al.
BRITISH JOURNAL OF CANCER (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
p53 in health and disease
Karen H. Vousden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
HS Phillips et al.
CANCER CELL (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis
R Abounader et al.
NEURO-ONCOLOGY (2005)
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
DA Haas-Kogan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas
D Pauleit et al.
BRAIN (2005)
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
AB Heimberger et al.
CLINICAL CANCER RESEARCH (2005)
C-11-methionine PET as a prognostic marker in patients with glioma: comparison with F-18-FDG PET
S Kim et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity
X Xu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas
MF Paz et al.
CLINICAL CANCER RESEARCH (2004)
Genetic pathways to glioblastoma:: A population-based study
H Ohgaki et al.
CANCER RESEARCH (2004)
Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C→A:T mutations of the TP53 tumor suppressor gene
M Nakamura et al.
CARCINOGENESIS (2001)
Promoter hypermethylation of the RB1 gene in glioblastomas
M Nakamura et al.
LABORATORY INVESTIGATION (2001)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
